184 related articles for article (PubMed ID: 28263231)
1. Appendix-derived Pseudomyxoma Peritonei (PMP): Molecular Profiling Toward Treatment of a Rare Malignancy.
Gleeson EM; Feldman R; Mapow BL; Mackovick LT; Ward KM; Morano WF; Rubin RR; Bowne WB
Am J Clin Oncol; 2018 Aug; 41(8):777-783. PubMed ID: 28263231
[TBL] [Abstract][Full Text] [Related]
2. Genomic profile of pseudomyxoma peritonei analyzed using next-generation sequencing and immunohistochemistry.
Nummela P; Saarinen L; Thiel A; Järvinen P; Lehtonen R; Lepistö A; Järvinen H; Aaltonen LA; Hautaniemi S; Ristimäki A
Int J Cancer; 2015 Mar; 136(5):E282-9. PubMed ID: 25274248
[TBL] [Abstract][Full Text] [Related]
3. Molecular profiles of high-grade and low-grade pseudomyxoma peritonei.
Noguchi R; Yano H; Gohda Y; Suda R; Igari T; Ohta Y; Yamashita N; Yamaguchi K; Terakado Y; Ikenoue T; Furukawa Y
Cancer Med; 2015 Dec; 4(12):1809-16. PubMed ID: 26475379
[TBL] [Abstract][Full Text] [Related]
4. Molecular profiling of appendiceal epithelial tumors using massively parallel sequencing to identify somatic mutations.
Liu X; Mody K; de Abreu FB; Pipas JM; Peterson JD; Gallagher TL; Suriawinata AA; Ripple GH; Hourdequin KC; Smith KD; Barth RJ; Colacchio TA; Tsapakos MJ; Zaki BI; Gardner TB; Gordon SR; Amos CI; Wells WA; Tsongalis GJ
Clin Chem; 2014 Jul; 60(7):1004-11. PubMed ID: 24821835
[TBL] [Abstract][Full Text] [Related]
5. The mutational landscape and prognostic indicators of pseudomyxoma peritonei originating from the ovary.
Wang B; Yao J; Ma R; Liu D; Lu Y; Shi G; An L; Xia A; Chen F; Pang S; Zhai X; Liu G; Chen S; Xu M; Song L; Xu H
Int J Cancer; 2021 Apr; 148(8):2036-2047. PubMed ID: 33403690
[TBL] [Abstract][Full Text] [Related]
6. Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis.
Borazanci E; Millis SZ; Kimbrough J; Doll N; Von Hoff D; Ramanathan RK
J Gastrointest Oncol; 2017 Feb; 8(1):164-172. PubMed ID: 28280620
[TBL] [Abstract][Full Text] [Related]
7. Pathological prognostic factors of pseudomyxoma peritonei: comprehensive clinicopathological analysis of 155 cases.
Yan F; Lin Y; Zhou Q; Chang H; Li Y
Hum Pathol; 2020 Mar; 97():9-18. PubMed ID: 31926211
[TBL] [Abstract][Full Text] [Related]
8. Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer.
Tokunaga R; Xiu J; Johnston C; Goldberg RM; Philip PA; Seeber A; Naseem M; Lo JH; Arai H; Battaglin F; Puccini A; Berger MD; Soni S; Zhang W; Hwang JJ; Shields AF; Marshall JL; Baba H; Korn WM; Lenz HJ
Clin Cancer Res; 2019 May; 25(10):3096-3103. PubMed ID: 30692096
[TBL] [Abstract][Full Text] [Related]
9. Global gene expression in pseudomyxoma peritonei, with parallel development of two immortalized cell lines.
Roberts DL; O'Dwyer ST; Stern PL; Renehan AG
Oncotarget; 2015 May; 6(13):10786-800. PubMed ID: 25929336
[TBL] [Abstract][Full Text] [Related]
10. Kras mutations and p53 overexpression in pseudomyxoma peritonei: association with phenotype and prognosis.
Shetty S; Thomas P; Ramanan B; Sharma P; Govindarajan V; Loggie B
J Surg Res; 2013 Mar; 180(1):97-103. PubMed ID: 23199549
[TBL] [Abstract][Full Text] [Related]
11. Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites.
El-Deiry WS; Vijayvergia N; Xiu J; Scicchitano A; Lim B; Yee NS; Harvey HA; Gatalica Z; Reddy S
Cancer Biol Ther; 2015; 16(12):1726-37. PubMed ID: 26553611
[TBL] [Abstract][Full Text] [Related]
12. Molecular genetic analysis of appendiceal mucinous adenomas in identical twins, including one with pseudomyxoma peritonei.
Shih IM; Yan H; Speyrer D; Shmookler BM; Sugarbaker PH; Ronnett BM
Am J Surg Pathol; 2001 Aug; 25(8):1095-9. PubMed ID: 11474297
[TBL] [Abstract][Full Text] [Related]
13. Targeted Next-Generation Sequencing Improves the Prognostication of Patients with Disseminated Appendiceal Mucinous Neoplasms (Pseudomyxoma Peritonei).
Wald AI; Pingpank JF; Ongchin M; Hall LB; Jones H; Altpeter S; Liebdzinski M; Hamed AB; Derby J; Nikiforova MN; Bell PD; Paniccia A; Zureikat AH; Gorantla VC; Rhee JC; Thomas R; Bartlett DL; Smith K; Henn P; Theisen BK; Shyu S; Shalaby A; Choudry MHA; Singhi AD
Ann Surg Oncol; 2023 Nov; 30(12):7517-7526. PubMed ID: 37314541
[TBL] [Abstract][Full Text] [Related]
14. GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study.
Pietrantonio F; Berenato R; Maggi C; Caporale M; Milione M; Perrone F; Tamborini E; Baratti D; Kusamura S; Mariani L; Niger M; Mennitto A; Gloghini A; Bossi I; Settanni G; Busico A; Bagnoli PF; Di Bartolomeo M; Deraco M; de Braud F
J Transl Med; 2016 May; 14(1):125. PubMed ID: 27154293
[TBL] [Abstract][Full Text] [Related]
15. Analysis of Mutation and Loss of Heterozygosity by Whole-Exome Sequencing Yields Insights into Pseudomyxoma Peritonei.
Pengelly RJ; Rowaiye B; Pickard K; Moran B; Dayal S; Tapper W; Mirnezami A; Cecil T; Mohamed F; Carr N; Ennis S
J Mol Diagn; 2018 Sep; 20(5):635-642. PubMed ID: 29936255
[TBL] [Abstract][Full Text] [Related]
16. Pseudomyxoma peritonei of a mature ovarian teratoma caused by mismatch repair deficiency in a patient with Lynch syndrome: a case report.
Gohda Y; Noguchi R; Horie T; Igari T; Nakamura H; Ohta Y; Yamaguchi K; Ikenoue T; Hatakeyama S; Yusa N; Furukawa Y; Yano H
BMC Med Genet; 2016 Dec; 17(1):94. PubMed ID: 27938333
[TBL] [Abstract][Full Text] [Related]
17. The biological basis and function of GNAS mutation in pseudomyxoma peritonei: a review.
Lin YL; Ma R; Li Y
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2179-2188. PubMed ID: 32700107
[TBL] [Abstract][Full Text] [Related]
18. Genetic diagnosis of pseudomyxoma peritonei originating from mucinous borderline tumor inside an ovarian teratoma.
Taguchi A; Rokutan H; Oda K; Tanikawa M; Tanimoto S; Sone K; Mori M; Tsuruga T; Kohsaka S; Tatsuno K; Shinozaki-Ushiku A; Miyagawa K; Mano H; Aburatani H; Ushiku T; Osuga Y
BMC Med Genomics; 2022 Mar; 15(1):51. PubMed ID: 35255903
[TBL] [Abstract][Full Text] [Related]
19. Expression of CEA, CA19-9, CA125, and EpCAM in pseudomyxoma peritonei.
Nummela P; Leinonen H; Järvinen P; Thiel A; Järvinen H; Lepistö A; Ristimäki A
Hum Pathol; 2016 Aug; 54():47-54. PubMed ID: 27038681
[TBL] [Abstract][Full Text] [Related]
20. MUC2 is a molecular marker for pseudomyxoma peritonei.
O'Connell JT; Hacker CM; Barsky SH
Mod Pathol; 2002 Sep; 15(9):958-72. PubMed ID: 12218214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
